Results 71 to 80 of about 11,087,757 (202)

Organic solar cells based on acceptor-functionalized diketopyrrolopyrrole derivatives [PDF]

, 2015
This work was supported by the EPSRC (grants EP/E036244 and EP/I00343X).The synthesis and characterization of three solution processable diketopyrrolopyrrole (DPP) derivatives featuring acceptor units attached to the core by alkyne linker units is ...
Rotello, Vince, Samuel, Ifor David William, Ghosh, Sanjay Sanatan, Serrano, Luis A., Cooke, Graeme, Ebenhoch, Bernd   +5 more
core   +1 more source

HK-2 viability inhibited by IS and restored by DPP-4 inhibitor.

, 2014
(A) Dose-dependent effect of IS on HK-2 cells viability. HK-2 cells were incubated with various concentration of IS for 3 days. (B) Dose-dependent effect of DPP-4 inhibitor on IS-treated HK-2 cells.
Chen-Hung Chang (586172), Mao-Feng Sun (586173), Wei-Jie Wang (186948), Sheng-Feng Hsu (586174), Ching-Sung Weng (586175)   +4 more
core   +1 more source

Antidiabetikus terápia DPP-4 gátlókkal-fókuszban a cardiovascularis biztonságosság

, 2017
A napjaink egyik legjelentősebb népegészségügyi problémáját jelentő 2-es típusú diabetes mellitus minél korábbi hatékony kezelése csökkenti a betegség szövődményeinek kialakulását és a meglévő szövődmények progresszióját is.
Paszternák, Judit
core  

Alogliptin: a new addition to the class of DPP-4 inhibitors

, 2009
Radha Andukuri, Andjela Drincic, Marc RendellDivision of Endocrinology, Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska, USABackground: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the ...
Radha Andukuri, Andjela Drincic, Marc Rendell   +2 more
core  

Inflammatory Bowel Disease in a Patient Returning from Colombia: Association with Dipeptidyl Peptidase 4 Inhibitor?

Case Reports in Gastroenterology
Introduction: Recent-onset colitis poses a diagnostic challenge, necessitating a thorough evaluation to identify potential infectious and non-infectious etiologies.
Ahmed B. Bayoumy, Gwen M.C. Masclee, Nanne K.H. de Boer, Andra Neefjes-Borst, Dirk Jan Stenvers   +4 more
doaj   +1 more source

Cost-effectiveness analysis of oral anti-diabetic medications: DPP-4 inhibitor as monotherapy vs. combination therapy in type 2 diabetic patients in Malang, Indonesia [PDF]

Background: Several anti-diabetic medications are covered under the Indonesian Universal Health Coverage (BPJS). However, metformin is typically prioritized over other options, such as DPP-4 inhibitors, because they are considered costly.
Sidek Ahmad, Zulkhairul Naim, Yurina, Valentina, Che Hasan, Muhammad Kamil, Oktaviana, Prita Aldilla, Triastuti, Efta   +4 more
core   +2 more sources

C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy

Journal of Diabetes Research, 2016
Background. Our aim was to define the conditions that affect therapeutic success when dipeptidyl peptidase-4 (DPP-4) inhibitor is added to metformin monotherapy. Materials and Methods. We reviewed the medical records of 56 patients who had received DPP-4
Sevin Demir, Sule Temizkan, Mehmet Sargin   +2 more
doaj   +1 more source

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice

, 2019
Incretin therapy has emerged as one of the most popular medications for type 2 diabetes. We have previously reported that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin attenuates neointima formation after vascular injury in non-diabetic mice ...
Toshihiko Yanase, Ryoko Motonaga, Takashi Fukuda, Takashi Nomiyama, Takeshi Horikawa, Yuriko Hamaguchi, Tomoko Tanaka, Makito Tanabe, Yuichi Terawaki, Hiroyuki Takahashi, Takako Kawanami   +10 more
core   +1 more source

Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand

, 2016
Unchalee Permsuwan,1 Piyameth Dilokthornsakul,2 Surasak Saokaew,2–4 Kednapa Thavorn,5–7 Nathorn Chaiyakunapruk2,4,8,9 1Faculty of Pharmacy Chiang Mai University, Chiang Mai, 2Center of Pharmaceutical Outcomes Research, Faculty of ...
Chaiyakunapruk N, Thavorn K, Dilokthornsakul P, Permsuwan U, Saokaew S   +4 more
core  

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes

Diabetes, Metabolic Syndrome and Obesity, 2013
Baptist GallwitzDepartment of Medicine IV, Eberhard-Karls-University Tübingen, Tübingen, GermanyAbstract: The first dipeptidyl-peptidase-IV (DPP-4) inhibitor for the treatment of type 2 diabetes became available in 2006. Since then, the
Gallwitz B
doaj